AbbVie’s QULIPTA and Amgen’s Imdylltra Score New EU Approvals for Migraine and Lung Cancer Indications

on

AbbVie and Amgen have recently secured European Union marketing authorizations for migraine and small‑cell lung cancer medicines, respectively, giving both already‑approved drugs a second EU indication and Amgen’s drug its first EU label.

Sources:

AbbVie Announces European Commission Approval of AQUIPTA ...

AbbVie Announces European Commission Approval of AQUIPTA ...

New treatment for relapsed extensive-stage small cell lung cancer

FDA Approves QULIPTA™ (atogepant), the First and Only Oral CGRP Receptor Antagonist Specifically Developed for the Preventive Treatment of Migraine

Aquipta | European Medicines Agency (EMA)

EUROPEAN COMMISSION APPROVES AMGEN'S IMDYLLTRA ...

Microsoft Word - AbbVie - Qulipta CM NOC Announcement - Press Release - FINAL EN

AbbVie takes step forward in Europe with migraine drug - Labiotech.eu

Summary Basis of Decision for Qulipta

AbbVie receives EC approval for Aquipta to treat migraine

FDA Approvals Roundup: Qulipta, Repatha, Erbitux - RAPS

AbbVie achieves win for migraine prevention drug Aquipta in Europe

FDA Approves QULIPTA , the First and Only Oral CGRP Receptor Antagonist Specifically Developed for the Preventive Treatment of Migraine

AbbVie Gets EU Nod for Aquipta as Acute Treatment for Migraine